| 英文名称 |
中文名称 |
CAS号 |
操作 |
| TL12-186 |
TL 12-186,多激酶降解PROTAC |
2250025-88-6 |
详细
|
| IR820-PTX |
化合物 IR820-PTX |
2250419-19-1 |
详细
|
| Aβ/tau aggregation-IN-1 |
AΒ/TAU AGGREGATION-IN-1 |
2252162-81-3 |
详细
|
| RAS GTPase inhibitor 1 |
RAS GTPase inhibitor 1 |
2252242-32-1 |
详细
|
| Sabatolimab |
SABATOLIMAB |
2252262-24-9 |
详细
|
| Feladilimab |
菲阿迪利单抗 |
2252518-85-5 |
详细
|
| BCL6-IN-3 |
BCL6-IN-3 |
2253878-44-1 |
详细
|
| Upifitamab |
UPIFITAMAB |
2254118-43-7 |
详细
|
| NLRP3-IN-17 |
化合物 NLRP3-IN-17 |
2254432-75-0 |
详细
|
| Fenitrooxone |
氧代杀螟硫磷 |
2255-17-6 |
详细
|
| Bafrekalant |
化合物 BAFREKALANT |
2256770-44-0 |
详细
|
| Isothiuronium |
2-undec-10-enylisothiouronium iodide |
22584-04-9 |
详细
|
| Rosopatamab |
罗索帕妥单抗 |
2260767-49-3 |
详细
|
| OSMI-3 |
OSMI-3 |
2260791-13-5 |
详细
|
| USP15-IN-1 |
化合物 USP15-IN-1 |
2260826-16-0 |
详细
|
| S2157 |
S2157 |
2262488-39-9 |
详细
|
| 4-PQBH |
化合物 4-PQBH |
2243355-51-1 |
详细
|
| DNDI-6148 |
N-(1-羟基-1,3-二氢苯并[C][1,2]氧杂环戊硼烷-6-基)-5-甲基-1-(2-吡啶基)-1H-1,2,3-三唑-4-甲酰胺 |
2243909-59-1 |
详细
|
| 2-Quinoxalinecarboxylic acid-d4 |
喹噁啉-2-羧酸-D4 |
2244217-89-6 |
详细
|
| Amine-PEG3-Lys(PEG3-N3)-PEG3-N3 |
化合物 AMINE-PEG3-LYS(PEG3-N3)-PEG3-N3 |
2244602-35-3 |
详细
|
| Idactamab |
IDACTAMAB (ANTI-SLC1A5) |
2245205-37-0 |
详细
|
| GSK-2807 free base |
GSK2807 |
2245255-65-4 |
详细
|
| ARX-1796 |
ARX-1796 |
2245880-46-8 |
详细
|
| Janelia Fluor 549 TFA |
JANELIA FLUOR 549 TFA |
2245946-45-4 |
详细
|
| Adebrelimab |
阿得贝利单抗 |
2247114-85-6 |
详细
|
| BY27 |
BY27 |
2247236-59-3 |
详细
|
| AW68 |
化合物 AW68 |
2247236-61-7 |
详细
|
| ITF3756 |
化合物ITF3756 |
2247608-27-9 |
详细
|
| AHR antagonist 5 |
(R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine |
2247953-39-3 |
详细
|
| STAT3-IN-13 |
化合物 STAT3-IN-13 |
2248552-86-3 |
详细
|
| Ziltivekimab |
ZILTIVEKIMAB (泽韦奇单抗 ) |
2226654-05-1 |
详细
|
| Itepekimab |
对照抗体 |
2226742-52-3 |
详细
|
| Tilvestamab |
TILVESTAMAB (替卫妥单抗 ) |
2226775-26-2 |
详细
|
| UNC5293 |
化合物 T9134 |
2226789-82-6 |
详细
|
| Favezelimab |
MAVEZELIMAB (玛维泽利单抗 ) |
2231068-83-8 |
详细
|
| BI-1408 |
BI-1408 |
2231075-94-6 |
详细
|
| ALDH1A1-IN-2 |
NCT-507 |
2231081-18-6 |
详细
|
| NCT-506 |
NCT-506 |
2231098-99-8 |
详细
|
| Vibostolimab (anti-TIGIT) |
VIBOSTOLIMAB (维博利单抗 ) |
2231305-30-7 |
详细
|
| BMT-090605 hydrochloride |
化合物 BMT-090605 HYDROCHLORIDE |
2231664-45-0 |
详细
|
| AZ2 |
AZ2 |
2231760-33-9 |
详细
|
| SHR1653 |
SHR1653 |
2231770-73-1 |
详细
|
| EMT inhibitor-2 |
EMT inhibitor-2 |
2232228-60-1 |
详细
|
| PDDC inhibitor |
(R)-(1-(3-(3,4-二甲氧基苯基)-2,6-二甲基咪唑并[1,2-B]哒嗪-8-基)吡咯烷-3-基)氨基甲酸苯酯 |
2232878-43-0 |
详细
|
| AP-C5 |
AP C5 |
2234272-10-5 |
详细
|
| cpd.5 of 2234271-86-2 |
化合物CPD.5 OF 2234271-86-2 |
2234284-82-1 |
详细
|
| (Iso)-Atagabalin HCl |
异构体ATAGABALIN盐酸盐 |
223445-68-9 |
详细
|
| HDAC6 degrader 9c |
HDAC6 degrader 9c |
2235382-05-3 |
详细
|
| Triflubazam |
三氟巴占 |
22365-40-8 |
详细
|
| DMA-135 hydrochloride |
化合物 DMA-135 HYDROCHLORIDE |
2237925-62-9 |
详细
|
| 22393-62-0_peak 2 |
化合物22393-62-0_PEAK 2 |
22393-63-1 |
详细
|
| Hu7691 free base |
化合物 HU7691 FREE BASE |
2241232-43-7 |
详细
|
| AUTAC1 |
化合物 AUTAC1 |
2241669-09-8 |
详细
|
| BTK inhibitor 10 |
BTK inhibitor 10 |
2241732-30-7 |
详细
|
| MMP-9-IN-6 |
化合物 MMP-9-IN-6 |
2241964-36-1 |
详细
|
| Tesnatilimab |
特拉佐利单抗 |
2242758-08-1 |
详细
|
| CFTR corrector 6 |
DAPAGLIFLOZIN |
2226970-01-8 |
详细
|
| CXCR7 modulator 2 |
CXCR7 modulator 2 |
2227426-37-9 |
详细
|
| Mezagitamab |
MEZAGITAMAB (迈泽妥单抗 ) |
2227490-52-8 |
详细
|
| HPK1-IN-19 |
|
2227609-33-6 |
详细
|
| Ragaglitazar |
222834-30-2 |
222834-30-2 |
详细
|
| HPK1-IN-26 |
化合物 HPK1-IN-26 |
2229042-24-2 |
详细
|
| ZL0454 |
ZL0454 |
2229042-77-5 |
详细
|
| Glofitamab |
格菲妥单抗 |
2229047-91-8 |
详细
|
| Avizakimab |
艾维奇单抗 |
2229685-51-0 |
详细
|
| Mirzotamab |
MIRZOTAMAB (米佐妥单抗 ) |
2229859-11-2 |
详细
|
| Alogabat |
ALOGABAT |
2230009-48-8 |
详细
|
| Lorpucitinib |
化合物 LORPUCITINIB |
2230282-02-5 |
详细
|
| KDM4-IN-4 |
化合物 KDM4-IN-4 |
2230475-63-3 |
详细
|
| JNJ-65355394 |
化合物 JNJ-65355394 |
2230598-99-7 |
详细
|
| RORγt inverse agonist 23 |
RORΓT INVERSE AGONIST 23 |
2230779-18-5 |
详细
|
| EHMT2-IN-1 |
EHMT2-IN-1 |
2230849-55-3 |
详细
|
| Ar-V7-IN-1 |
4-(4-(4,5-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine |
2230880-25-6 |
详细
|
| Serplulimab |
SERPLULIMAB (斯鲁利单抗 ) |
2231029-82-4 |
详细
|
| Nrf2 activator-1 |
(S)-ETHYL 3-(7-METHOXY-1-METHYL-1H-BENZO[D][1,2,3]TRIAZOL-5-YL)-3-(4-METHYL-3-(((R)-4-METHYL-1,1-DIO |
2230697-41-1 |
详细
|
| Revdofilimab |
化合物 REVDOFILIMAB |
2230138-89-1 |
详细
|
| GSK-3 inhibitor 3 |
GSK-3抑制剂3 |
2227279-84-5 |
详细
|
| GSK-3 inhibitor 4 |
GSK-3抑制剂4 |
2227279-83-4 |
详细
|
| Vixarelimab |
单抗VIXARELIMAB |
2243320-83-2 |
详细
|
| LY3372689 |
LY3372689 |
2241514-56-5 |
详细
|
| Nampt activator-2 |
NAMPT激活剂2 |
2237268-90-3 |
详细
|
| Atagabalin HCl |
ATAGABALIN盐酸盐 |
223445-67-8 |
详细
|
| Opevesostat |
/ |
2231294-96-3 |
详细
|
| Tubulin inhibitor 35 |
TUBULIN抑制剂35 |
2247047-77-2 |
详细
|
| Pirmitegravir |
吡米特格雷韦 |
2245231-10-9 |
详细
|
| Cudarolimab |
化合物 CUDAROLIMAB |
2244739-29-3 |
详细
|
| 3-Methyl-2-quinoxalinecarboxylic Acid-d4 |
3-甲基喹噁啉-2-羧酸(MQCA)-[D4 |
2244217-93-2 |
详细
|
| PARP1/2/TNKS1/2-IN-1 |
PARP1/2/TNKS1/2抑制剂1 |
2243453-32-7 |
详细
|
| TH-Z145 |
化合物TH-Z145 |
2260887-57-6 |
详细
|
| Bexmarilimab |
BEXMARILIMAB |
2259301-27-2 |
详细
|
| AMPC |
异型南五味子丁素 |
2254434-33-6 |
详细
|
| (2′S)-4′-O-β-D-apiofuranosyl-(1→6)-O-β-D-glucopyranosylvisamminol |
3'-O-Β-D-芹糖(1→6)-Β-D-葡萄糖维斯阿米醇 |
2254096-97-2 |
详细
|
| bisSP1 |
二叠氮胺接头 |
2253947-15-6 |
详细
|
| SY-LB-57 |
化合物 SY-LB-57 |
2253719-35-4 |
详细
|
| Pimicotinib |
化合物 PIMICOTINIB |
2253123-16-7 |
详细
|
| Oditrasertib |
ODITRASERTIB |
2252271-93-3 |
详细
|
| Pirepemat fumarate |
PIREPEMAT |
2251806-70-7 |
详细
|
| MEISi-2 |
化合物MEISI-2 |
2250156-71-7 |
详细
|
| ERα degrader-2 |
ERΑ降解剂2 |
2235396-63-9 |
详细
|